GeneDx Faces Securities Lawsuit After Fabric Genomics Impairment
A 49% stock collapse on May 5, 2026, has triggered a class action investigation into GeneDx Holdings. Hagens Berman is scrutinizing whether the company misled investors regarding the integration and synergy of its Fabric Genomics acquisition, which resulted in a $31.2 million impairment charge shortly after the deal closed.